Michael Yee
Stock Analyst at Jefferies
(2.77)
# 1,842
Out of 4,900 analysts
83
Total ratings
42.86%
Success rate
7.86%
Average return
Main Sectors:
Stocks Rated by Michael Yee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRGX CARGO Therapeutics | Maintains: Hold | $3.7 → $5 | $4.61 | +8.58% | 4 | Jul 8, 2025 | |
| BPMC Blueprint Medicines | Initiates: Buy | $135 | $129.35 | +4.37% | 1 | Mar 17, 2025 | |
| ALXO ALX Oncology Holdings | Upgrades: Buy | $2 → $3 | $0.47 | +543.09% | 5 | Mar 6, 2025 | |
| KOD Kodiak Sciences | Upgrades: Buy | $20 | $4.81 | +315.80% | 3 | Dec 9, 2024 | |
| BIIB Biogen | Downgrades: Hold | $250 → $180 | $127.50 | +41.18% | 5 | Dec 9, 2024 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Buy | $500 → $550 | $464.20 | +18.48% | 4 | Dec 9, 2024 | |
| AMGN Amgen | Maintains: Buy | $380 | $292.51 | +29.91% | 5 | Nov 12, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $40 → $45 | $14.17 | +217.57% | 2 | Nov 1, 2024 | |
| MRNA Moderna | Maintains: Hold | $65 → $55 | $31.58 | +74.16% | 8 | Oct 15, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $35 | $13.51 | +159.07% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $14.25 | +180.70% | 1 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $385 | $745.87 | -48.38% | 4 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1.4 → $10 | $2.13 | +369.48% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $3 | $4.18 | -28.23% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $75 → $30 | $19.58 | +53.22% | 2 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $60 → $20 | $15.83 | +26.34% | 8 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 → $20 | $38.76 | -48.40% | 3 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 → $75 | $8.50 | +782.35% | 1 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $3.03 | +890.10% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $65 | $35.15 | +84.92% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,875 → $1,125 | $7.32 | +15,268.85% | 2 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 → $30 | $1.13 | +2,554.87% | 4 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 → $30 | $6.23 | +381.93% | 3 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 | $18.15 | +561.16% | 2 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $70 → $75 | $20.37 | +268.19% | 2 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $22.96 | +30.66% | 1 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $77 | $14.04 | +448.43% | 2 | Nov 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $109.06 | - | 3 | Jan 26, 2018 |
CARGO Therapeutics
Jul 8, 2025
Maintains: Hold
Price Target: $3.7 → $5
Current: $4.61
Upside: +8.58%
Blueprint Medicines
Mar 17, 2025
Initiates: Buy
Price Target: $135
Current: $129.35
Upside: +4.37%
ALX Oncology Holdings
Mar 6, 2025
Upgrades: Buy
Price Target: $2 → $3
Current: $0.47
Upside: +543.09%
Kodiak Sciences
Dec 9, 2024
Upgrades: Buy
Price Target: $20
Current: $4.81
Upside: +315.80%
Biogen
Dec 9, 2024
Downgrades: Hold
Price Target: $250 → $180
Current: $127.50
Upside: +41.18%
Vertex Pharmaceuticals
Dec 9, 2024
Upgrades: Buy
Price Target: $500 → $550
Current: $464.20
Upside: +18.48%
Amgen
Nov 12, 2024
Maintains: Buy
Price Target: $380
Current: $292.51
Upside: +29.91%
Denali Therapeutics
Nov 1, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $14.17
Upside: +217.57%
Moderna
Oct 15, 2024
Maintains: Hold
Price Target: $65 → $55
Current: $31.58
Upside: +74.16%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $13.51
Upside: +159.07%
Sep 13, 2024
Initiates: Buy
Price Target: $40
Current: $14.25
Upside: +180.70%
Jul 17, 2024
Initiates: Buy
Price Target: $385
Current: $745.87
Upside: -48.38%
Mar 27, 2024
Upgrades: Buy
Price Target: $1.4 → $10
Current: $2.13
Upside: +369.48%
Mar 15, 2024
Downgrades: Hold
Price Target: $16 → $3
Current: $4.18
Upside: -28.23%
Dec 8, 2023
Downgrades: Hold
Price Target: $75 → $30
Current: $19.58
Upside: +53.22%
Oct 25, 2023
Downgrades: Hold
Price Target: $60 → $20
Current: $15.83
Upside: +26.34%
Oct 25, 2023
Upgrades: Buy
Price Target: $8 → $20
Current: $38.76
Upside: -48.40%
Jan 6, 2023
Upgrades: Buy
Price Target: $63 → $75
Current: $8.50
Upside: +782.35%
Nov 15, 2021
Initiates: Buy
Price Target: $30
Current: $3.03
Upside: +890.10%
Mar 2, 2021
Initiates: Buy
Price Target: $65
Current: $35.15
Upside: +84.92%
Mar 2, 2021
Downgrades: Hold
Price Target: $1,875 → $1,125
Current: $7.32
Upside: +15,268.85%
Feb 12, 2021
Downgrades: Hold
Price Target: $40 → $30
Current: $1.13
Upside: +2,554.87%
Feb 12, 2021
Upgrades: Buy
Price Target: $15 → $30
Current: $6.23
Upside: +381.93%
Nov 6, 2020
Downgrades: Hold
Price Target: $120
Current: $18.15
Upside: +561.16%
Oct 12, 2020
Upgrades: Buy
Price Target: $70 → $75
Current: $20.37
Upside: +268.19%
Sep 14, 2020
Initiates: Buy
Price Target: $30
Current: $22.96
Upside: +30.66%
Nov 8, 2018
Assumes: Buy
Price Target: $77
Current: $14.04
Upside: +448.43%
Jan 26, 2018
Upgrades: Buy
Price Target: n/a
Current: $109.06
Upside: -